The city of Minneapolis, Minnesota, currently has 3 active clinical trials seeking participants for Migraine research studies.
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: Clinical Research Institute Inc, Minneapolis, Minnesota
Conditions: Migraine
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Recruiting
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/07/2024
Locations: Teva Investigational Site 14270, Minneapolis, Minnesota
Conditions: Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical out... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/28/2024
Locations: Teva Investigational Site 14270, Minneapolis, Minnesota
Conditions: Migraine